Clofutriben shows promise in trial for endogenous Cushing’s syndrome
All patients who completed a Phase 2 clinical trial of clofutriben, an oral small molecule that Sparrow Pharmaceuticals is developing for endogenous Cushing’s syndrome, chose to continue on the experimental treatment as part of a planned open-label extension. Overall, the results of the trial, dubbed RESCUE, showed promise, Sparrow…